Andipal (Andipal)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceBendazole + Metamizol sodium + Papaverine + PhenobarbitalBendazole + Metamizol sodium + Papaverine + Phenobarbital
Similar drugsTo uncover
  • Andipal
    pills inwards 
    UZOLE-SIBERIAN CHEMICAL PLANT, OJSC     Russia
  • Andipal
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Andipal
    pills inwards 
    PHARMSTANDART-TOMSKHIMFARM, OJSC     Russia
  • Andipal
    pills inwards 
    Barnaul Plant of Medical Preparations, LLC     Russia
  • Andipal
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Andipal
    pills inwards 
    MOSCOW ENDOCRINE FACTORY, FSUE     Russia
  • Andipal
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Andipal
    pills inwards 
    UZOLE-SIBERIAN CHEMICAL PLANT, OJSC     Russia
  • Andipal Avexima
    pills inwards 
    ASFARMA, LLC     Russia
    • Dosage form: & nbsppills
    Composition:

    Active substances: metamizole sodium (analgin) 250 mg, phenobarbital 20 mg, dibazol (bendazole) 20 mg, papaverine hydrochloride 20 mg.

    Excipients: potato starch - 47 mg, talc - 10 mg, calcium stearate - 3 mg.

    Description:Tablets white or white with a weak yellow shade of color, flat-cylindrical with a risk and a facet.
    Pharmacotherapeutic group:Analgesic agent (aaalgeziruyuschee and non-narcotic means + spasmolytic agent + barbiturate)
    ATX: & nbsp

    N.02.B.B.52   Metamizole sodium in combination with other drugs, excluding psycholeptics

    Pharmacodynamics:

    Combined drug.The combination of the components of the drug leads to a mutual enhancement of their pharmacological action.

    Metamizole sodium - a derivative of pyrazolone, has an analgesic and antipyretic effect.

    Dibasol (benzazole) - a vasodilating agent; has a vasodilating action, stimulates the function of the spinal cord. Has direct spasmolytic effect on smooth muscles of blood vessels and internal organs. It facilitates synoptic transmission in the spinal cord.

    Papaverina hydrochloride is an antispasmodic, has hypotensive effect, reduces tone and relaxes smooth muscles of internal organs and vessels. Phenobarbital, in small doses has a sedative effect and enhances the effect of other components.

    Indications:

    Pain syndrome (mild or moderate) with spasms of smooth muscles of internal organs: renal colic, biliary colic, intestinal colic, dyskinesia of bile ducts, postcholecystectomy syndrome, spasm of ureters and bladder, algodismenorea.

    Spasm of cerebral vessels, migraine.

    In the quality of an auxiliary drug: pain syndrome after surgeryand diagnostic procedures.

    Contraindications:Hypersensitivity (including the derivatives of pyrazolone); oppression of bone marrow hematopoiesis; marked hepatic and / or renal insufficiency; deficiency of glucose-6-phosphate dehydrogenase, tachyarrhythmias, severe angina pectoris, collapse, decompensated chronic heart failure; angle-closure glaucoma; hyperplasia of the prostate; intestinal obstruction, megacolon; pregnancy, lactation.
    Dosing and Administration:Inside for 1 tablet 2-3 times a day. Duration is applicable without consulting a doctor should not exceed 7 days.
    Side effects:

    Allergic reactions.

    From the central nervous system: drowsiness, decreased speed of psychomotor reactions.

    From the gastrointestinal tract: nausea, constipation.

    From the cardiovascular system: arterial hypertension.

    With prolonged use: leukopenia; agranulocytosis, dysfunction of the liver and kidneys.

    Interaction:

    Combination with nitrates (nitroglycerine, nitrosorbit, suture, etc.), calcium channel blockers (nifedipine, corinfar, etc.) beta-blockers (anaprilin, metoprolol, talinolol and others), ganglion blockers (pentamine, etc.), diuretics (furosemide, hypothiazide, etc.), myotropic antispasmodics (dipyridamole, eufillin, etc.) enhances the hypotensive effect of these drugs.

    Simultaneous use with other non-narcotic analgesics can lead to mutual enhancement of toxic effects.

    Joint application with adsorbents, astringents and enveloping agents reduces the absorption of the drug in the gastrointestinal tract.

    Special instructions:

    At long (more than 7 days) application control of a picture of peripheric blood and a functional status of a liver is necessary. If there is no effect within 3 days, stop taking the drug and consult a doctor.

    Effect on the ability to drive transp. cf. and fur:During treatment should be abandoned the employment of potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
    Form release / dosage:Pills.
    Packaging:

    10 tablets per contour cell or cell-free packaging.

    Two contour squares with instructions for medical use are placed in a pack of cardboard.

    Contour non-cellular packages with an equal number of instructions for medical use or a pack of cardboard are placed in a group package.

    Storage conditions:In a dry place protected from light. Keep out of the reach of children.
    Shelf life:

    2 years 6 months

    After expiration date the drug should not be used.

    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-006417/08
    Date of registration:08.08.2008 / 14.08.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:IRBITSK HFZ, OJSC IRBITSK HFZ, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp05.09.2017
    Illustrated instructions
      Instructions
      Up